Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses

Why this matters to everyday life

Bird flu headlines can sound distant—outbreaks in poultry farms or wild birds halfway around the world. But the H5N1 strain of avian influenza has a track record of killing more than half of the people it infects, and a recently expanded lineage is now spreading widely in birds, sea mammals, and even cattle. This study explores a laboratory-made antibody, called FNI9, that latches onto a key viral protein and powerfully blocks a broad array of H5N1 viruses. The work points to a new kind of emergency protection that could help shield high‑risk people if this dangerous virus ever starts spreading easily from person to person.

The growing bird flu threat

Since the late 1990s, a family of H5N1 viruses descended from an outbreak in geese in Guangdong, China, has steadily expanded across the globe. These viruses have devastated poultry industries, threatened food security in low‑income countries, and repeatedly jumped into humans, causing severe disease with high fatality rates. A newer offshoot, known as clade 2.3.4.4b, has become panzootic—established across continents in birds and increasingly found in mammals such as foxes, dolphins, minks, and dairy cattle. Some of these animal viruses carry mutations that help flu replicate better in human cells, raising concern that only a few evolutionary steps may stand between today’s outbreaks and a future human pandemic.

Limits of current drugs and vaccines

Modern medicine is not empty‑handed against influenza, but its tools have gaps. The frontline drug oseltamivir, which targets the viral neuraminidase protein, can reduce disease if given early, yet resistant viruses have already been seen in H5N1 infections. Experimental “universal” flu vaccines have been in development for years, but only a few have progressed beyond animal testing, and even licensed H5 vaccines may become mismatched as the virus evolves. Vaccines can also produce weaker or short‑lived responses in older adults and people with weakened immune systems, who are often those at greatest risk. In a fast‑moving outbreak, medical teams need countermeasures that are both broad—covering many viral variants—and immediately protective.

A broadly acting antibody against H5N1

The researchers focused on FNI9, a monoclonal antibody that recognizes neuraminidase, the viral protein that helps newly formed flu particles escape from infected cells. Using a sensitive laboratory test that mimics natural conditions, they compared FNI9’s ability to block neuraminidase with that of two approved drugs, oseltamivir and peramivir. Across a panel of viral “pseudoparticles” carrying neuraminidase from many H5N1 lineages collected over nearly three decades—including the widely circulating 2.3.4.4b variants from birds, cattle, and recent human cases—FNI9 consistently matched or outperformed the drugs. Importantly, it remained highly effective against neuraminidase versions that carry known resistance mutations to oseltamivir, suggesting it could work even when standard antivirals fail.

Protection in animals and how it works

To test whether this lab activity translates into real‑world protection, the team gave single doses of FNI9 to mice one day before exposing them to lethal doses of H5N1 viruses. Against a modified, less deadly H5N1 strain, even low doses of FNI9 completely prevented death and significantly reduced weight loss, a sign of milder illness. When challenged with a fully virulent H5N1 virus from the 2.3.4.4b lineage, FNI9 again protected most or all animals, depending on the dose and challenge intensity, and reduced signs of both respiratory disease and nervous system involvement. At higher antibody doses, mice survived severe viral challenges that killed all untreated animals. These results indicate that a single preventive infusion of FNI9 can offer strong, short‑term protection in this animal model.

Hidden viral weak spot and low escape potential

The investigators then asked why FNI9 works against so many versions of H5N1 and whether the virus could easily evolve to escape it. Using cryo‑electron microscopy, they visualized FNI9 bound to neuraminidase from an earlier H5N1 strain at near‑atomic detail. The antibody inserts a loop into the enzyme’s active groove, making a dense network of contacts with seven amino acids that are crucial for neuraminidase’s function. Computer simulations and global sequence analyses showed that these seven positions are almost unchanged across tens of thousands of H5N1 samples from birds, humans, and other mammals collected since 1997. When the team used machine‑learning models to score all possible mutations at these key sites, most changes either looked harmful to the virus or unlikely to spread. Only one predicted escape mutation showed even a modest chance of gaining ground—and it would require multiple genetic steps to arise.

What this could mean in a future outbreak

Taken together, the study suggests that FNI9 targets a deeply conserved “Achilles’ heel” on H5N1’s neuraminidase, combining broad coverage with high potency and a low likelihood of viral escape. While much work remains—testing safety and dosing in larger animals and, eventually, humans—such antibodies could be stockpiled as “off‑the‑shelf” tools for emergency use. In a scenario where a dangerous H5N1 strain begins spreading among people, FNI9‑like antibodies might be deployed to protect frontline health workers, farm staff, and vulnerable patients, buying crucial time while vaccines are updated and rolled out.

Citation: Moriyama, S., di Iulio, J., Zatta, F. et al. Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses. Nat Commun 17, 3351 (2026). https://doi.org/10.1038/s41467-026-70036-8

Keywords: H5N1 avian influenza, monoclonal antibody FNI9, neuraminidase inhibition, pandemic preparedness, broad-spectrum antivirals